• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.ACHN-490 单独及与其他药物联合对铜绿假单胞菌的活性。
Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.
2
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.由一株产PER-1超广谱β-内酰胺酶的铜绿假单胞菌引起的大鼠实验性肺炎的治疗。
J Antimicrob Chemother. 1999 Jul;44(1):91-7. doi: 10.1093/jac/44.1.91.
3
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.头孢吡肟、哌拉西林-他唑巴坦或美罗培南与环丙沙星联合治疗对多重耐药铜绿假单胞菌菌株的体外活性。
Chemotherapy. 2003 Dec;49(6):294-7. doi: 10.1159/000074529.
4
In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.体外协同抗生素组合对多重耐药铜绿假单胞菌的疗效。
Yonsei Med J. 2010 Jan;51(1):111-6. doi: 10.3349/ymj.2010.51.1.111. Epub 2009 Dec 29.
5
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].[耐碳青霉烯类鲍曼不动杆菌的耐药机制及体外联合用药的应用]
Zhonghua Shao Shang Za Zhi. 2014 Apr;30(2):166-70.
6
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.头孢吡肟、哌拉西林/他唑巴坦、庆大霉素、环丙沙星和左氧氟沙星单独及联合应用对铜绿假单胞菌的作用。
Diagn Microbiol Infect Dis. 2002 Sep;44(1):35-41. doi: 10.1016/s0732-8893(02)00420-0.
7
In vitro antimicrobial activity of doripenem, a new carbapenem.新型碳青霉烯类药物多利培南的体外抗菌活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96. doi: 10.1128/AAC.48.4.1384-1396.2004.
8
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.铜绿假单胞菌对碳青霉烯类和哌拉西林/他唑巴坦的耐药模式。
J Chemother. 1999 Apr;11(2):93-6. doi: 10.1179/joc.1999.11.2.93.
9
Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.β-内酰胺类药物对耐亚胺培南但对头孢他啶敏感的铜绿假单胞菌的抗菌作用
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00054-17. Print 2017 Jun.
10
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.新型广谱β-内酰胺类抗生素对肠杆菌科细菌和非发酵菌的体外活性:来自奥地利重症监护病房的报告。奥地利碳青霉烯敏感性监测组
Wien Klin Wochenschr. 1999 Jul 30;111(14):549-54.

引用本文的文献

1
Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.解锁氨基糖苷类抗生素对铜绿假单胞菌的增强疗效。
Microb Biotechnol. 2025 Jun;18(6):e70174. doi: 10.1111/1751-7915.70174.
2
The transcriptional regulators of virulence for : Therapeutic opportunity and preventive potential of its clinical infections.毒力的转录调节因子:其临床感染的治疗机遇与预防潜力
Genes Dis. 2022 Oct 1;10(5):2049-2063. doi: 10.1016/j.gendis.2022.09.009. eCollection 2023 Sep.
3
A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.2011年至2015年抗氨基糖苷类耐药性及毒性相关专利综述。
Medchemcomm. 2016;7(1):50-68. doi: 10.1039/C5MD00453E. Epub 2015 Nov 19.
4
Antibiotics and bacterial resistance in the 21st century.21世纪的抗生素与细菌耐药性
Perspect Medicin Chem. 2014 Aug 28;6:25-64. doi: 10.4137/PMC.S14459. eCollection 2014.
5
Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.克服氨基糖苷类修饰酶作用的策略用于治疗耐药菌感染。
Future Med Chem. 2013 Jul;5(11):1285-309. doi: 10.4155/fmc.13.80.
6
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.10 x '20 进展——开发针对革兰氏阴性杆菌的新型药物:来自美国传染病学会的最新进展。
Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.

本文引用的文献

1
Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City.新型氨基糖苷类抗生素 ACHN-490 对来自纽约市鲍曼不动杆菌和铜绿假单胞菌的抗菌活性。
J Antimicrob Chemother. 2011 Feb;66(2):332-4. doi: 10.1093/jac/dkq459. Epub 2010 Dec 3.
2
Multidrug-resistant Gram-negative bacteria: how to treat and for how long.耐多药革兰氏阴性菌:如何治疗及治疗时长。
Int J Antimicrob Agents. 2010 Dec;36 Suppl 2:S50-4. doi: 10.1016/j.ijantimicag.2010.11.014. Epub 2010 Dec 3.
3
Combating evolution with intelligent design: the neoglycoside ACHN-490.用智能设计对抗进化:新型糖基化合物 ACHN-490。
Curr Opin Microbiol. 2010 Oct;13(5):565-73. doi: 10.1016/j.mib.2010.09.004.
4
Synthesis and spectrum of the neoglycoside ACHN-490.ACHN-490 糖基化合物的合成与光谱研究。
Antimicrob Agents Chemother. 2010 Nov;54(11):4636-42. doi: 10.1128/AAC.00572-10. Epub 2010 Aug 30.
5
Treatment options for multidrug-resistant nonfermenters.多重耐药非发酵菌的治疗选择。
Expert Rev Anti Infect Ther. 2010 Mar;8(3):303-15. doi: 10.1586/eri.09.125.
6
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.采用时间杀菌法检测 ACHN-490 单药及与其他药物联合的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2010 May;54(5):2258-61. doi: 10.1128/AAC.01350-09. Epub 2010 Feb 9.
7
Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.非发酵革兰氏阴性菌中的耐药性:最大程度的多重耐药。
Am J Med. 2006 Jun;119(6 Suppl 1):S29-36; discussion S62-70. doi: 10.1016/j.amjmed.2006.03.014.
8
Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.导致医院获得性肺炎的潜在多重耐药非发酵革兰氏阴性病原体。
Int J Antimicrob Agents. 2006 Mar;27(3):183-95. doi: 10.1016/j.ijantimicag.2005.11.005. Epub 2006 Feb 10.

ACHN-490 单独及与其他药物联合对铜绿假单胞菌的活性。

Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.

机构信息

Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.

出版信息

Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.

DOI:10.1128/AAC.01390-10
PMID:21282445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3088216/
Abstract

ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. Each combination was synergistic against most isolates at 24 h, and antagonism was not observed. Combinations of ACHN-490 with cefepime, doripenem, imipenem, or piperacillin-tazobactam yielded synergies in ≥70% and ≥80% of strains at 6 and 12 h, respectively, and in ≥68% at 24 h.

摘要

ACHN-490 与头孢吡肟、多利培南、亚胺培南或哌拉西林他唑巴坦联合用于协同时间杀伤分析,以测试其对 25 株具有不同耐药表型的铜绿假单胞菌菌株的单独作用和联合作用。大多数分离株在 24 小时时,每种组合对大多数分离株均具有协同作用,且未观察到拮抗作用。ACHN-490 与头孢吡肟、多利培南、亚胺培南或哌拉西林他唑巴坦联合使用,在 6 小时和 12 小时时,分别在≥70%和≥80%的菌株中产生协同作用,在 24 小时时在≥68%的菌株中产生协同作用。